ACSL4 and neoplasm: In addition, miRNAs-449 were found to be downregulated in doxorubicin-resistant cells, whereas ACSL4 was found to be overexpressed in both doxorubicin-resistant cells and in tumor samples from patients who relapsed after receiving chemotherapy, which was also associated with a worse DFS in TNBC patients.